Skip to Main Content
Contribute Try STAT+ Today

On Friday, an advisory committee to the Food and Drug Administration is reviewing aducanumab, the Alzheimer’s disease treatment developed by Biogen. We’ll be monitoring the meeting and posting analysis throughout the day. Updates will be posted in reverse chronological order.

As a reminder of why this meeting matters: If approved, aducanumab would become the first new Alzheimer’s therapy in nearly two decades — and the first drug to reduce cognitive decline by targeting and eliminating clumps of a toxic protein called beta amyloid that are believed to destroy the brain.

For Biogen, of course, the drug would be a blockbuster. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.